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Phase-specific and lifetime costs of cancer
care in Ontario, Canada
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Jeffrey S. Hoch7, Stuart Peacock8 and Murray D. Krahn9
Abstract
Background: Cancer is a major public health issue and represents a significant economic burden to health care
systems worldwide. The objective of this analysis was to estimate phase-specific, 5-year and lifetime net costs for
the 21 most prevalent cancer sites, and remaining tumour sites combined, in Ontario, Canada.
Methods: We selected all adult patients diagnosed with a primary cancer between 1997 and 2007, with valid ICD-O site
and histology codes, and who survived 30 days or more after diagnosis, from the Ontario Cancer Registry (N = 394,092).
Patients were linked to treatment data from Cancer Care Ontario and administrative health care databases at the Institute
for Clinical and Evaluative Sciences. Net costs (i.e., cost difference between patients and matched non-cancer control
subjects) were estimated by phase of care and sex, and used to estimate 5-year and lifetime costs.
Results: Mean net costs of care (2009 CAD) were highest in the initial (6 months post-diagnosis) and terminal
(12 months pre-death) phases, and lowest in the (3 months) pre-diagnosis and continuing phases of care.
Phase-specific net costs were generally lowest for melanoma and highest for brain cancer. Mean 5-year net
costs varied from less than $25,000 for melanoma, thyroid and testicular cancers to more than $60,000 for
multiple myeloma and leukemia. Lifetime costs ranged from less than $55,000 for lung and liver cancers to over
$110,000 for leukemia, multiple myeloma, lymphoma and breast cancer.
Conclusions: Costs of cancer care are substantial and vary by cancer site, phase of care and time horizon analyzed.
These cost estimates are valuable to decision makers to understand the economic burden of cancer care and may be
useful inputs to researchers undertaking cancer-related economic evaluations.
Keywords: Health care costs, Cancer, Neoplasms, Administrative data, Cost and cost analysis
Background
Cancer is a major public health issue and represents a sig-
nificant economic burden to health care systems worldwide.
In Ontario, Canada’s largest province, as of January 1, 2013,
362,557 people had been diagnosed with cancer over the
last 10 years (about 2.7 % of the population) [1]. The num-
ber of new cases diagnosed annually is expected to more
than double from 29,649 in 1981 to 85,648 in 2016, mostly
due to aging and population growth [1]. The development
of new and expensive treatments has resulted in high
cancer-related costs post-diagnosis, which have been in-
creasing over time [2]. For example, for patients age 45+,
mean costs nearly doubled for breast and colorectal cancers
from 1997 to 2007 ($12,909 and $24,769 to $29,362 and
$43,964, respectively), and increased by roughly 50 % for
prostate and lung cancers for the same period (from
$11,490 and $22,037 to $15,170 and $34,471, respectively)
[2]. A thorough understanding of the burden of cancer care
is required to ensure an optimal use of scarce health care
resources. Cancer cost estimates can help inform national
programs and related policies, and are an important input
for economic evaluations.
Many of the seminal studies that have measured cancer
costs have employed the “phase of care” approach, making
it a standard method to estimate disease-related costs over
time. One of its appealing aspects is that it incorporates the
natural history of the disease and corresponding patterns of
treatment. Furthermore, when applied to survival data, it
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enables the estimation of long-term costs [3, 4]. Baker and
colleagues (1991) were the first to employ this method to
breast and lung cancers [5]; other studies have extended
this work [3, 6, 7]. One study estimated phase-specific and
5-year costs for the 18 most prevalent cancers in elderly pa-
tients in the United States [4]. The authors found that
mean net costs were highest in the initial and terminal
phases of care, and lowest in the continuing phase of care
[4]. Most research in the United States has examined pa-
tients 65+ only; more recent work undertaken elsewhere
has included patients 18+ [7, 8]. Few studies have been able
to account for all relevant direct costs incurred by patients
with cancer [4, 7, 8].
In Canada, medically necessary health care is funded for
all permanent residents through universal public health care
insurance plans managed by provincial/territorial govern-
ments. In Ontario, residents are covered by the Ontario
Ministry of Health and Long-Term Care (MOHLTC). This
includes services provided in hospital and by physicians as
well as other services. In many cases, once care is provided
outside of hospitals, patients may be required to pay out-of-
pocket for direct medical costs, such as prescription drugs
or home care.
The purpose of this study was to estimate the mean net
costs for the 21 most prevalent cancers (and all remaining
tumour sites combined) by phase of care for all patients 18
+, from the perspective of the public third-party payer. In
addition, it estimated 5-year and lifetime (25-year) costs for
all 21 cancer sites. This study presents more comprehensive
mean net costs than previous work by including, for ex-
ample, costs of all physician services (including primary
care) and of long-term care. Furthermore, it provides
population-based cost estimates for the entire adult popula-
tion over the age of 18. These estimates are lacking in the
literature and will be useful to decision makers and re-
searchers in other jurisdictions, given similar patterns of
care across most developed countries.
Methods
Study setting
We conducted a matched cohort study to evaluate all costs
incurred by the public third-party payer (MOHLTC) for pa-
tients whose first diagnosis for a primary cancer occurred
between January 1, 1997 and December 31, 2007, and who
survived more than 30 days after diagnosis. All costs were
adjusted to 2009 Canadian dollars [9]. The study was ap-
proved by the institutional review board at Sunnybrook
Health Sciences Centre, Toronto, Canada and the Univer-
sity of Toronto Research Ethics Board.
Patient and control selection
Patients were identified from the Ontario Cancer Registry,
a population-based cancer registry for the province of
Ontario (population 13.2 million) [10]. The Ontario
Cancer Registry captures approximately 95 % of all cancer
diagnoses in the province of Ontario; it has been shown to
be both accurate and reliable [11–14]. We included all
patients 18+ assigned a single, valid International Classifi-
cation of Diseases-Oncology (ICD-O) topography code
corresponding to a primary cancer, and with no second
cancer diagnosed within 90 days of the initial diagnosis.
We classified patients into one of the 21 most prevalent
cancer sites: head and neck, esophagus, gastric, colorectal,
liver, pancreas, lung, melanoma, prostate, female breast
(hereafter referred to as breast), corpus uteri, cervix, ovary,
bladder, renal, brain, lymphoma, multiple myeloma,
leukemia, thyroid and testis. We also examined an
additional category consisting of all other cancer sites
combined. For each site, we selected the 20 most frequent
histology codes, which were reviewed by two practising
oncologists to ensure our cohort was representative of
current clinical practice (see Additional file 1: Table S1).
Controls (patients without cancer) were selected from
the Registered Persons Database, a population-based regis-
try of all residents eligible for public health care insurance
in Ontario. To be eligible for health care in Ontario,
patients must either be a Canadian citizen, a permanent
resident or among one of the newcomer groups eligible
under Ontario’s Health Insurance Act; reside in the
province, and be present in the province for a specified
amount of time [15]. We included individuals 18+ with
no cancer diagnosis before or during our analysis period
and that used the health care system in the year prior to
their assigned pseudo-diagnosis date.
Cases (cancer patients) and controls were matched 1:1
at two index dates – date of diagnosis and 12 months
preceding the date of death (for those who died during
the observation period). For the first index date, each
control was randomly assigned a pseudo-diagnosis
date based on the month and year of diagnosis of the
matched cancer patient in our sample. For the latter
index date, controls who died were matched on the
same date of death as the cancer patient. To match
each case to a control, we calculated a propensity
score of having cancer, through the use of a logit
model, using age, sex, neighbourhood income quintile
at the Census tract level [16], “rural and small town”
indicator from Statistics Canada [17], comorbidity,
measured by the Johns Hopkins aggregated diagnosis
groups (excluding aggregated diagnosis group 32 –
malignancy) [18] in the year prior to the index date,
and residence in a long-term care facility at index
date. We selected the closest control that met the fol-
lowing criteria: age +/− 2 years at the index date; same
sex (hard match); and a propensity score within a caliper
width of 0.05 standard deviations [19]. We were able to
find a suitable control for 98 % (N = 393,154) of our initial
cohort (N = 402,399).
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Data sources
We obtained data on all patients from pre-diagnosis to
diagnosis and treatment to recovery/survivorship and/or
end-of-life care (Fig. 1). Cancer-specific treatment data
(chemotherapy and radiation therapy data) were obtained
from Cancer Care Ontario, the provincial agency respon-
sible for improving cancer services in Ontario. Data on all
other resources from pre-diagnosis to recovery/survivorship
and/or end-of-life care were obtained from the Institute for
Clinical Evaluative Sciences in Toronto, Ontario. The
combined set of databases included: New Drug Fund-
ing Program (chemotherapy), Activity Level Reporting
System (radiation therapy), Ontario Health Insurance
Plan claims database (all physician services, including
primary care physicians, specialists and other physicians,
and diagnostic tests and laboratory services), Ontario Drug
Benefit program database (outpatient prescription drugs for
patients age 65+ and/or on social assistance only),
Canadian Institute for Health Information-Discharge
Abstract Database (inpatient hospitalizations), Canadian
Institute for Health Information-National Ambulatory Care
Reporting System (ambulatory care, which includes same-
day surgeries/procedures and emergency department visits),
Continuing Care Reporting System (other institution-based
care), Ontario Home Care Administrative System and
Home Care Database (home care). (See Additional file 1:
Table S2 for a detailed description.) These databases have
been described and validated in the literature; the collection
and reporting of the data by hospitals and other health care
institutions follow the Ontario Healthcare Reporting
Standards/Management Information Systems [20]. Fur-
thermore, these databases have been used in previous
work as a source of data for costing analyses in Ontario
[2, 21, 22]. They include the cost of the vast majority of
health care resources covered under the Ontario public
health care insurance plan (roughly 90 %) [20]; how-
ever, they do not cover costs with community service
agencies. In addition, they do not capture costs covered
under private health care plans, such as costs with
outpatient prescription drugs for patients under the age
of 65, and other health care costs paid out-of-pocket.
All datasets were linked through the use of unique
encoded identifiers and analyzed at the Institute for
Clinical Evaluative Sciences.
Cost estimates for inpatient hospitalizations, same-day
surgeries/procedures and emergency department visits
were obtained by multiplying the resource intensity weight
(measure of resource utilization intensity) by the cost per
weighted case (unit cost) [20, 23–25]. Cost estimates for
other resources were either available in the data or ob-
tained from other sources [20, 26]. The costing methods
followed the guidelines of the Canadian Agency for Drugs
and Technology in Health [27] and were based on previ-
ous cancer costing work done in Ontario [2, 21, 22].
Study design and analysis
Phase-specific net costs of care
All analyses were done using SAS ® version 9.2. We used
a phase-based approach [4, 5, 28, 29] to estimate costs
incurred before and after diagnosis, and to account for
differences in follow up time. All patients had a pre-
diagnosis phase, which we defined as the 3 months before
diagnosis. This phase typically includes diagnostic testing
to establish the cancer diagnosis [30, 31]. We divided the
time between diagnosis and death into three clinically
relevant phases of care: 1) initial, which includes the pri-
mary course of therapy and any adjuvant therapy, and
defined as the 6 months after diagnosis (including date of
diagnosis); 2) continuing, which encompasses ongoing
surveillance and active follow-up treatment for cancer re-
currence and/or new primary cancers, and expressed as
an annual estimate; and 3) terminal, which captures the
intensive services, often palliative in nature, provided in
the 12 months before death. The lengths of the phases
were based on clinical knowledge of the disease and join-
point analysis [4, 5, 32]. We employed the same length
across all sites to ensure comparability. Patients who died
had their observation time, up to 12 months, first assigned
Fig. 1 Cancer care continuum in Ontario. Source: Ontario Cancer Plan IV 2015-2019, Cancer Care Ontario https://cancercare.on.ca/common/
pages/UserFile.aspx?fileId=333871
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to the terminal phase; any remaining time, as well as all
time of patients who survived, was then assigned to the
initial phase and finally to the continuing phase [29].
We employed the ‘net cost’ method [28, 29] to obtain
an estimate of the cost attributable to cancer. This
method consists of subtracting the costs incurred by
patients from those incurred by matched controls. The
mean net cost (C) for each phase of care and cancer site
was defined as C phase = C
P
phase - C
C
phase, where C denotes
mean net cost, and subscripts P and C denote patient
and control subjects, respectively. The corresponding
variance was defined as Var (C phase) = Var (C
P
phase) + Var
(C Cphase).
1 Mean net costs were estimated for each cancer
site, sex and phase of care. We also calculated confi-
dence intervals (CIs) for each cost estimate through
Taylor series expansion based on asymptotic assump-
tions [33]. Costs by resource were also estimated and
are available upon request.
Mean 1- and 5-year net costs of care
We estimated mean undiscounted 1- and 5-year net
costs (C1Y and C5Y, respectively) by applying monthly
survival probabilities, obtained from Cancer Care Ontario,
to the mean monthly net cost estimates for patients in the
initial, continuing, and terminal phases described above.
Mean 1- and 5-year net costs, respectively, were calculated
as follows, where Initi, Conti, Termi represent the amount
of time each patient spent in month i in the initial, con-
tinuing and terminal phases, respectively; Cinit, Ccont and
Cterm represent the phase-specific net cost, and Pi
AD repre-
sents the probability of dying of any cause (cancer- or
non-cancer-related) in month i [4]2:
C1Y ¼ Cinit 
X
i
Pi
AD  Initi
 
þ Ccont 
X
i
Pi
AD  Conti
 
þ Cterm 
X
i
Pi
AD  Termi
 
þ 1 ‐
X
i
P24
AD
 
 6  Cinit þ 6  Ccontð Þ;
where i ¼ 1; …; 23f g;
C5Y ¼ Cinit 
X
i
Pi
AD  Initi
 
þ Ccont 
X
i
Pi
AD  Conti
 
þ Cterm 
X
i
Pi
AD  Termi
 
þ 1 ‐
X
i
P72
AD
 
 6  Cinit þ 54  Ccontð Þ;
where i ¼ 1; …; 71f g:
To estimate 1-year net costs, we used monthly survival
probabilities for 24 months as patients who died in the
second year after diagnosis (13 ≤month i < 24) would
have been in their last year of life for some portion of
the first year, thus incurring terminal costs in both time
periods. We applied the same rule to estimate
undiscounted 5-year net costs, in line with previous
work [4]. We also estimated mean discounted 5-year net
costs using a 5 % discount rate annually [18]. We calcu-
lated 95 % CIs for each estimate.
Mean lifetime net costs of care
We combined phase-specific cost estimates with long-term
survival curves to calculate undiscounted and discounted
lifetime costs from diagnosis to death, in line with previous
research [29]. This was done by taking a weighted average
of estimated cancer-related costs for patients surviving
different lengths of time, up to 25 years after diagnosis. We
calculated 95 % CIs for each estimate. One of the limitations
of this approach is that long-term survival tends to have
lower continuing care costs than short-term survivals [29].
Results
Patients
Table 1 describes the characteristics of the cohort of
matched cancer patients (N = 394,092). The majority had
breast, prostate, colorectal and lung cancers (≈60 %
combined). Patients had a mean age of 63 years; 51 %
were male. They were fairly equally distributed across
neighbourhood income quintiles and lived mostly in
urban areas (85 %); few lived in long-term facilities (1 %)
at diagnosis. Approximately half required speciality care
(55 %) (i.e. an unstable chronic condition) in the year
prior to diagnosis. Most patients were diagnosed in the
later years of our analysis period.
Controls were fairly well matched to cases. The quality
of the match was generally better for cases matched at
diagnosis than those matched 12 month before death,
and for cancer sites with larger numbers of patients (not
shown; results can be found in the Additional files 2 and 3).
Phase-specific net costs of care
Mean net costs were highest in the initial and terminal
care phases, and lowest in the pre-diagnosis and con-
tinuing care phases, following a u-shaped curve from
diagnosis to death (Table 2; Additional file 1: Figure S1).
For the 3-month pre-diagnosis phase, net costs were
lowest for bladder ($236 and $217, for men and women
respectively) and esophagus for women only ($221). Net
costs for this phase were highest for liver ($3381 and
$2893 for men and women, respectively) and multiple
myeloma ($3142 and $2609 for men and women, re-
spectively). High pre-diagnosis costs were mainly due to
diagnostic testing and hospital admissions.
Net costs increased greatly in the 6-month initial phase
and were highest for esophageal, brain, pancreas and gastric
cancers. Costs for these sites were greater than $29,000,
with the highest cost for esophageal cancer ($41,567 and
$42,658 for men and women, respectively). Net costs were
lowest for melanoma ($4649 and $4110 for men and
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women, respectively). Costs were mainly due to hospital
admissions and, to a lesser extent, physician services.
Net costs decreased for the continuing phase and were
highest for multiple myeloma ($15,153 and $15,255 for
men and women, respectively), and lowest for testicular
cancer for men ($2264) and gastric cancer for women
($2660). Hospital admissions and other institution-based
care made up the bulk of the total cost.
Net costs were highest in the 12-month terminal phase
of care. These were greater than $70,000 for patients
with brain ($72,463 and $81,385 for men and women,
respectively) and testicular cancers ($77,814), and lowest
for melanoma ($18,494 and $16,115 for men and women,
respectively), prostate ($17,391) and breast ($18,593)
cancers. Again, the main drivers of costs were hospital
admissions and, to a lesser extent, home and other
institution-based care.
For most cancer sites and phases (except the pre-
diagnosis phase), CIs did not overlap among males
and females, suggesting cost differences by sex. The
exceptions were esophageal cancer in the initial phase,
and lymphoma, colorectal and thyroid cancers in the
continuing phase, indicating similarity in costs. There
Table 1 Characteristics of patients diagnosed with cancer
Characteristic Number Percent
Overall sample 394,092 100.0
Type of cancer
Breast (female) 68,147 17.3
Prostate 67,539 17.1
Colorectal 56,635 14.4
Lung 41,378 10.5
Melanoma 16,892 4.3
Head and neck 12,291 3.1
Corpus uteri 12,109 3.1
Bladder 12,048 3.1
Thyroid 11,339 2.9
Lymphoma 10,246 2.6
Renal 9861 2.5
Leukemia 7897 2.0
Gastric 7889 2.0
Ovary 6999 1.8
Pancreas 6231 1.6
Brain 5358 1.4
Cervix 4753 1.2
Esophagus 4261 1.1
Myeloma 4214 1.1
Testis 3015 0.8
Liver 2580 0.7
Other tumours 22,410 5.7
Age in years at diagnosis
Mean (SD) 63.4 (13.9) –
Median (IQR) 65 (54–74) –
Sex
Male 201,050 51.0
Female 193,042 49.0
Neighbourhood income quintile
1 – Low 74,465 18.9
2 – Medium-low 80,541 20.4
3 – Medium 78044 19.8
4 – Medium-High 78,250 19.9
5 - High 82,792 21.0
Urban/rural residence
Urban 336,275 85.3
Rural 57,817 14.7
Residence in long-term care facility 3972 1.0
Collapsed Ambulatory Diagnostic Group
Acute Minor 39,667 10.1
Acute Major 124,683 31.6
Likely to recur 58,043 14.7
Table 1 Characteristics of patients diagnosed with cancer
(Continued)
Asthma 2327 0.6
Chronic, unstable 217,622 55.2
Chronic, stable 75,512 19.2
Specialty, unstable 6304 1.6
Specialty, stable 2488 0.6
Eye, dental 9576 2.4
Psychosocial 12,616 3.2
Prevention 39,324 1.0
Pregnancy 1237 0.3
Year of diagnosis
1997 30,839 7.8
1998 31,230 7.9
1999 32,437 8.2
2000 33,792 8.6
2001 35,222 8.9
2002 35,911 9.1
2003 35,724 9.1
2004 37,848 9.6
2005 39,423 10.0
2006 40,374 10.2
2007 41,292 10.5
SD Standard deviation, IQR inter-quartile range
Data sources: Ontario Cancer Registry, Canada Census data, Statistics Canada
Postal Code Conversion File and administrative health care data housed at the
Institute for Clinical Evaluative Sciences
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Table 2 Mean net costs of care by phase of care and tumour sitea
Tumour Site Phase, estimated cost (95 % CI)
Pre-diagnosis (3 months) Initial (6 months) Continuing (annual) Terminal (12 months)
Males
Head and neck $595 ($326–$865) $19,702 ($19,691–$19,714) $5151 ($5143–$5159) $37,346 ($37,332–$37,360)
Esophagus $818 ($455–$1180) $41,567 ($41,539–$41,596) $5491 ($5474–$5509) $54,354 ($54,336–$54,371)
Gastric $848 ($481–$1215) $32,240 ($32,203–$32,278) $3329 ($3315–$3342) $53,708 ($53,695–$53,722)
Colorectal $275 (−$101-$651) $25,138 ($25,131–$25,146) $5446 ($5442–$5451) $32,408 ($32,401–$32,415)
Liver $3381 ($2906–$3855) $21,355 ($21,325–$21,384) $11,954 ($11,937–$11,971) $30,265 ($30,242–$30,289)
Pancreas $1892 ($1468–$2315) $29,979 ($29,950–$30,008) $6296 ($6272–$6319) $54,152 ($54,138–$54,167)
Lung $1833 ($1458–$2209) $22,409 ($22,402–$22,417) $5533 ($5526–$5539) $39,241 ($39,236–$39,247)
Melanoma $553 ($331–$774) $4649 ($4635–$4664) $4005 ($3998–$4012) $18,494 ($18,479–$18,509)
Prostate $637 ($375–$899) $8394 ($8391–$8397) $5017 ($5015–$5020) $17,391 ($17,385–$17,397)
Bladder $236 (−$189–$661) $10,429 ($10,412–$10,447) $3394 ($3386–$3403) $35,749 ($35,737–$35,760)
Renal $1503 ($1111–$1895) $14,950 ($14,936–$14,964) $3991 ($3981–$4002) $38,292 ($38,274–$38,309)
Brain $1548 ($1192–$1904) $33,241 ($33,227–$33,225) $6563 ($6546–$6581) $72,463 ($72,444–$72,483)
Lymphoma $1484 ($1125–$1843) $17,831 ($17,820–$17,842) $6276 ($6268–$6285) $59,202 ($59,182–$59,222)
Myeloma $3142 ($2675–$3609) $24,447 ($24,418–$24,476) $15,153 ($15,138–$15,169) $43,989 ($43,969–$44,010)
Leukemia $1325 ($1006–$1645) $18,214 ($18,194–$18,233) $8035 ($8024–$8045) $74,857 ($74,837–$74,877)
Thyroid $1020 ($757–$1282) $9837 ($9828–$9846) $3382 ($3372–$3391) $33,459 ($33,408–$33,511)
Testis $1325 ($1106–$1544) $11,201 ($11,190–$11,211) $2264 ($2255–$2273) $77,814 ($77,721–$77,907)
All other tumour sitesb $1469 ($1075–$1862) $18,730 ($18,720–$18,740) $5878 ($5870–$5886) $42,047 ($42,037–$42,057)
Females
Head and neck $1217 ($877–$1557) $20,242 ($20,212–$20,271) $7049 ($7032–$7065) $36,382 ($36,361–$36,402)
Esophagus $221 (−$218–$660) $42,658 ($42,633–$42,684) $6744 ($6703–$6785) $51,728 ($51,699–$51,757)
Gastric $681 ($214–$1149) $29,940 ($29,922–$29,958) $2660 ($2634–$2685) $52,551 ($52,533–$52,570)
Colorectal $542 ($122–$963) $24,765 ($24,753–$24,777) $5349 ($5343–$5355) $31,120 ($31,113–$31,127)
Liver $2893 ($2441–$3346) $19,331 ($19,252–$19,411) $7764 ($7707–$7821) $27,850 ($27,813–$27,888)
Pancreas $1716 ($1282–$2150) $31,953 ($31,924–$31,981) $8734 ($8702–$8767) $53,320 ($53,303–$53,337)
Lung $2047 ($1648–$2445) $21,583 ($21,571–$21,596) $6251 ($6243–$6260) $35,664 ($35,657–$35,671)
Melanoma $437 ($236–$638) $4110 ($4097–$4122) $3872 ($3864–$3880) $16,115 ($16,095–$16,134)
Female breast $1216 ($944–$1487) $12,219 ($12,213–$12,224) $6741 ($6738–$6744) $18,593 ($18,587–$18,598)
Corpus uteri $852 ($558–$1145) $12,083 ($12,073–$12,093) $3320 ($3312–$3327) $22,577 ($22,560–$22,593)
Cervix $781 ($554–$1007) $14,448 ($14,442–$14,454) $2833 ($2823–$2842) $31,796 ($31,774–$31,819)
Ovary $1490 ($1155–$1825) $22,532 ($22,518–$22,546) $4100 ($4089–$4110) $34,670 ($34,657–$34,684)
Bladder $217 (−$222–$655) $10,886 ($10,850–$10,923) $5127 ($5109–$5145) $37,087 ($37,069–$37,105)
Renal $2335 ($1883–$2787) $15,602 ($15,573–$15,632) $4525 ($4511–$4539) $40,810 ($40,787–$40,834)
Brain $2004 ($1619–$2389) $30,683 ($30,669–$30,697) $9883 ($9854–$9912) $81,385 ($81,360–$81,411)
Lymphoma $1838 ($1488–$2187) $16,885 ($16,860–$16,910) $6274 ($6263–$6285) $43,600 ($43,579–$43,621)
Myeloma $2609 ($2077–$3140) $24,052 ($24,012–$24,092) $15,255 ($15,238–$15,272) $45,871 ($45,849–$45,892)
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was no clear pattern in the ranking of costs by cancer site
between sexes. Hospitalizations comprised the largest
portion of net costs across all post-diagnosis phases
(not shown; results available upon request).
Mean 1-year, 5-year and lifetime net costs of care
The proportion of patients alive 1 year after diagnosis was
greater than 95 % for testicular, thyroid, prostate and
breast cancers, and melanoma, but only 30 % for patients
with pancreatic cancer (Table 3). Undiscounted mean
1-year net costs were lowest for melanoma, thyroid and
prostate cancers, and highest for esophageal cancer.
One-year net costs accounted for roughly 80 % of the
undiscounted 5-year net cost for esophageal and
pancreatic cancers.
The proportion of patients alive 5 years after diagnosis
was greater than 90 % for testicular and thyroid cancers
only, and less than 20 % for those with esophageal and
pancreatic cancers (Table 3). Undiscounted mean 5-year
net costs varied quite a bit across cancer sites, from less
than $25,000 for melanoma, thyroid and testicular cancers
to more than $55,000 for multiple myeloma and leukemia.
The same findings held for discounted mean 5-year net
costs. In addition, we mapped the association between
discounted 5-year net costs by the percentage of patients
alive 5 years after diagnosis for males and females. We
found that costs followed an inverted U-shaped curve with
survival (Fig. 2).
Discounted lifetime net costs ranged from less than
$50,000, for melanoma, liver (females only), testicular
and lung cancers, to over $95,000, for leukemia and
multiple myeloma (Table 4).
Discussion
We used administrative health care data to estimate
phase-specific, 5-year and lifetime net costs for the 21
most prevalent cancers individually and all other cancer
sites combined. Our findings suggest that cancer-related
costs are substantial and vary by cancer site, phase of
care and time horizon of analysis. We found that net costs
followed a U-shaped curve consistent with previous
research ([4, 7, 8, 21] de Oliveira C, Pataky R, Bremner K,
et al. Estimating the cost of cancer care in British Columbia
and Ontario: a Canadian inter-provincial comparison,
submitted), where costs were higher in the initial and ter-
minal phases, and lower in the pre-diagnosis and continuing
phases. Five-year and lifetime costs were generally highest
among patients diagnosed with hematological cancers.
Disease-specific estimates of costs are of great import-
ance in the health economics and health policy fields [34].
These estimates can be used to help justify screening and
intervention programs, provide a foundation for policy
and planning relative to prevention and control initiatives,
and assist in the allocation of research funds to specific
diseases. Furthermore, phase-specific cost estimates con-
stitute an important input for economic evaluations, in
particular those designed to evaluate prevention and
screening interventions.
Our findings are largely in accordance with previous
work using SEER-Medicare data in the United States [4].
Yabroff et al. (2008) also found that net costs in the initial
phase were highest for cancers with low survival, such as
brain, pancreas, esophageal and gastric cancers, and lowest
for cancers with high survival, such as melanoma and
prostate cancer [4]. These findings are also in line with
other research examining patients 18+ [8].
The ranking of our mean discounted 5-year net costs
was similar to that found in the SEER-Medicare popula-
tion as well. Previous research found high 5-year costs for
esophageal cancer and lymphoma, and low 5-year costs
for melanoma [4]. Furthermore, we found that cancers
with 5-year relative survival rates between roughly 40 and
66 % tended to have the highest mean net costs, similar to
findings from New Zealand [8]. As suggested by Blakely et
al. (2015), the idea is that patients with cancers with poor
prognosis, such pancreatic cancer, as well as those with
cancers with good prognosis, such as melanoma and
thyroid cancer, do not consume high costs, as the former
do not live long while the latter are able to respond more
fully to initial treatment [8]. Patients with the highest 5-
year net costs are those with average prognosis cancers,
such as multiple myeloma and leukemia, who consume
Table 2 Mean net costs of care by phase of care and tumour sitea (Continued)
Leukemia $706 ($301–$1112) $24,256 ($24,236–$24,276) $9949 ($9933–$9965) $69,531 ($69,507–$69,556)
Thyroid $946 ($725–$1167) $9098 ($9093–$9102) $3396 ($3390–$3402) $28,704 ($28,654–$28,754)
All other tumour sitesb $1455 ($1059–$1850) $18,288 ($18,271–$18,305) $5790 ($5780–$5800) $43,214 ($43,202–$43,226)
aThe initial phase of care is the first 6 months following diagnosis, the terminal phase is the final 12 months of life, and the continuing phase is all the months
between the initial and last year of life phases. Net costs in the continuing phase of care are an annual estimate. Net costs in the last year of life combine the cost
for cancer patients dying of cancer and those dying of other causes. All estimates are in 2009 dollars
bAll other tumour sites includes salivary gland, small intestine, appendix, intrahepatic bile duct, gallbladder and extrahepatic bile ducts, unspecified digestive
organs, pleura, thymus, heart, mediastinum, other respiratory organs, bones and joints, reticulo-endothelial, spleen, connective tissue/nerves, retroperitoneum and
peritoneum, soft tissue, breast (male only), labia and clitoris, vulva, vagina, other female genitals, placenta, penis, epididymis, spermatic cord, scrotum, other and
unspecified male genitals, other urinary organs, ureter, eye, orbit and lacrimal gland, eye (unspecified), cerebral and spinal meninges, meninges NOS, spinal cord,
cranial nerves, other nervous system, adrenal glands, parathyroid gland, pituitary gland, craniopharyngeal duct, pineal gland, other endocrine glands and
miscellaneous (ill-defined and unknown organs)
Data sources: Cancer Care Ontario and administrative health data housed at the Institute for Clinical Evaluative Sciences
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Table 3 Mean 5-year net costs of care by tumour site*
Tumour Site % alive after diagnosis Undiscounted costs, $ (95 % CI) 5-year discounted costs
at 5 %, $ (95 % CI)
Year 1 Year 5 Year 1 Year 5
Males
Head and neck 82.4 56.9 $25,127 ($25,112–$25,141) $44,305 ($44,270–$44,340) $42,336 ($42,303–$42,369)
Esophagus 43.0 13.4 $38,833 ($38,814–$38,852) $49,260 ($49,230–$49,291) $48,348 ($48,319–$48,378)
Gastric 50.9 20.3 $33,633 ($33,611–$33,654) $44,852 ($44,819–$44,885) $43,887 ($43,855–$43,919)
Colorectal 84.1 55.8 $27,149 ($27,140–$27,158) $46,892 ($46,872–$46,913) $44,874 ($44,855–$44,893)
Liver 54.5 25.0 $21,044 ($21,022–$21,067) $35,020 ($34,981–$35,059) $33,680 ($33,643–$33,718)
Pancreas 29.5 7.7 $28,067 ($28,054–$28,080) $34,181 ($34,161–$34,202) $33,661 ($33,641–$33,681)
Lung 43.1 15.3 $22,468 ($22,463–$22,473) $29,788 ($29,780–$29,797) $29,150 ($29,142–$29,159)
Melanoma 94.0 75.5 $8171 ($8153–$8188) $23,022 ($22,981–$23,063) $21,440 ($21,401–$21,478)
Prostate 96.9 83.9 $11,267 ($11,262–$11,271) $30,322 ($30,308–$30,336) $28,219 ($28,206–$28,232)
Bladder 84.6 58.2 $16,678 ($16,660–$16,697) $31,776 ($31,736–$31,815) $30,223 ($30,186–$30,260)
Renal 83.6 65.8 $20,613 ($20,597–$20,629) $33,853 ($33,817–$33,890) $32,500 ($32,466–$32,535)
Brain 49.2 20.1 $29,142 ($29,131–$29,154) $39,489 ($39,460–$39,518) $38,370 ($38,343–$38,397)
Lymphoma 84.7 66.2 $25,830 ($25,815–$25,845) $50,085 ($50,048–$50,122) $47,540 ($47,506–$47,574)
Myeloma 79.5 40.1 $31,938 ($31,908–$31,967) $68,056 ($67,997–$68,115) $64,414 ($64,358–$64,470)
Leukemia 79.3 58.2 $30,642 ($30,622–$30,662) $59,335 ($59,292–$59,378) $56,420 ($56,380–$56,461)
Thyroid 96.7 91.6 $12,153 ($12,138–$12,168) $26,361 ($26,309–$26,413) $24,789 ($24,742–$24,837)
Testis 98.6 96.2 $14,010 ($13,993–$14,027) $24,049 ($23,996–$24,103) $22,919 ($22,870–$22,968)
All other tumour sites 72.6 47.4 $22,525 ($22,515–$22,535) $38,459 ($38,436–$38,482) $36,868 ($36,846–$36,890)
Females
Head and neck 80.8 57.9 $25,254 ($25,222–$25,285) $47,882 ($47,811–$47,953) $45,474 ($45,407–$45,540)
Esophagus 41.6 16.3 $37,896 ($37,870–$37,922) $47,490 ($47,440–$47,540) $46,638 ($46,590–$46,685)
Gastric 49.9 24.5 $31,748 ($31,731–$31,766) $41,482 ($41,442–$41,522) $40,601 ($40,563–$40,639)
Colorectal 83.7 58.1 $25,849 ($25,837–$25,861) $44,187 ($44,160–$44,213) $42,303 ($42,278–$42,328)
Liver 54.5 21.1 $18,394 ($18,340–$18,448) $29,933 ($29,829–$30,036) $28,846 ($28,747–$28,944)
Pancreas 29.9 7.6 $28,940 ($28,925–$28,956) $35,610 ($35,584–$35,635) $35,017 ($34,992–$35,041)
Lung 50.7 21.6 $21,909 ($21,901–$21,918) $31,010 ($30,996–$31,025) $30,184 ($30,170–$30,197)
Melanoma 96.1 84.8 $6717 ($6701–$6734) $21,533 ($21,487–$21,578) $19,907 ($19,865–$19,949)
Female breast 96.6 81.8 $15,752 ($15,745–$15,758) $40,543 ($40,526–$40,560) $37,821 ($37,805–$37,837)
Corpus uteri 94.5 81.8 $14,284 ($14,270–$14,298) $27,818 ($27,777–$27,859) $26,345 ($26,307–$26,383)
Cervix 90.5 73.3 $18,160 ($18,148–$18,172) $30,815 ($30,774–$30,857) $29,495 ($29,457–$29,533)
Ovary 82.1 45.5 $25,740 ($25,723–$25,757) $42,352 ($42,314–$42,391) $40,734 ($40,698–$40,770)
Bladder 77.5 52.5 $17,567 ($17,533–$17,602) $34,625 ($34,552–$34,698) $32,864 ($32,795–$32,932)
Renal 85.5 70.2 $21,281 ($21,253–$21,310) $36,096 ($36,038–$36,154) $34,546 ($34,491–$34,601)
Brain 48.7 24.9 $32,686 ($32,672–$32,700) $45,533 ($45,500–$45,566) $44,293 ($44,262–$44,323)
Lymphoma 87.4 70.5 $21,451 ($21,425–$21,477) $43,729 ($43,671–$43,787) $41,338 ($41,283–$41,392)
Myeloma 79.9 40.0 $31,650 ($31,613–$31,686) $68,302 ($68,233–$68,371) $64,672 ($64,606–$64,737)
Leukemia 78.1 58.2 $32,326 ($32,304–$32,348) $61,659 ($61,603–$61,715) $58,597 ($58,544–$58,649)
Thyroid 98.9 97.2 $10,976 ($10,968–$10,984) $24,644 ($24,610–$24,677) $23,100 ($23,070–$23,130)
All other tumour sites 70.9 47.6 $22,558 ($22,543–$22,573) $38,678 ($38,645–$38,710) $37,056 ($37,025–$37,087)
* Phase-specific net cost of care estimates were applied to 5-year survival probabilities among cancer patients diagnosed 1997–2007. All cost estimates are in
2009 dollars
Data sources: Ontario Cancer Registry data (survival), and Cancer Care Ontario and administrative health data housed at the Institute for Clinical Evaluative
Sciences (mean net costs by phase of care)
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more resources due to recurrences and available treat-
ments that are able to extend survival [8].
We found lifetime net costs were highest among
hematological cancers, such as leukemia, multiple myeloma
and lymphoma, and breast cancer. Few studies have
estimated lifetime costs for all cancer sites; most have
examined either colorectal [29, 34, 35] or prostate cancers
[36] only. Our lifetime cost for colorectal cancer was higher
than the SEER-Medicare estimate. This difference, in
addition to the high lifetime costs for breast cancer and
leukemia, is likely due to the inclusion of younger patients
in our sample. The SEER-Medicare data include patients
age 65+ only. Cost estimates using the SEER-Medicare data
do not include the higher costs for younger cancer patients
who are typically treated with more aggressive surgical care
and/or adjuvant treatment than their older counterparts
[4], and who have higher survival rates. Furthermore,
given that younger non-cancer patients (controls) tend
to utilize the health care system less than older non-
cancer patients, costs tend to be lower in younger
control subjects, thus leading to higher net costs in
younger cancer patients [4]. At the aggregate level,
costs are likely higher for the four most prevalent can-
cer sites, such as prostate, breast, colorectal and lung,
due to the higher incidence and survival [22], but also
for leukemia and lymphoma, given their high lifetime
costs and relatively high incidence rates [37].
Our estimates are based on data from 1997 to 2007,
which were available to us at the time, and may not be
reflective of more recent diffusion of newer chemotherapy
agents and other changes in cancer care. This may be
particularly relevant for sites, such as melanoma and prostate
cancer, where the recent introduction of expensive drugs,
such as ipilimumab (for melanoma), and abiraterone (for
prostate cancer), have likely contributed to higher treatment
costs. Given these recent innovations, it will be important for
future research to examine these changes on costs.
Nonetheless, this study provides relevant insight on how
costs vary across all major cancer sites and phases of care.
Furthermore, our study employed rich administrative data
Fig. 2 Association between discounted 5-year net costs by percentage of patients alive 5 years after diagnosis for males a and females b (trendline is
a polynomial of order 2)
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Table 4 Mean lifetime (25-year) net costs of care by tumour site*
Tumour Site Undiscounted costs, $ (95 % CI) Discounted costs at 5 %, $ (95 % CI)
Males
Head and neck $83,700 ($83,627–$83,774) $66,249 ($66,194–$66,305)
Esophagus $77,260 ($77,210–$77,311) $69,048 ($69,005–$69,092)
Gastric $73,490 ($73,435–$73,545) $64,624 ($64,578–$64,670)
Colorectal $86,536 ($86,494–$86,579) $68,686 ($68,654–$68,718)
Liver $60,501 ($60,435–$60,567) $51,587 ($51,531–$51,643)
Pancreas $65,495 ($65,458–$65,531) $57,666 ($57,635–$57,697)
Lung $52,356 ($52,341–$52,371) $46,041 ($46,029–$46,054)
Melanoma $60,591 ($60,490–$60,693) $42,224 ($42,153–$42,296)
Prostate $79,147 ($79,110–$79,184) $56,156 ($56,129–$56,182)
Bladder $64,729 ($64,646–$64,811) $50,036 ($49,973–$50,098)
Renal $68,757 ($68,673–$68,840) $53,992 ($53,930–$54,054)
Brain $100,364 ($100,287–$100,441) $88,322 ($88,258–$88,386)
Lymphoma $114,574 ($114,484–$114,665) $85,723 ($85,657–$85,788)
Myeloma $118,255 ($118,156–$118,354) $96,847 ($96,766–$96,929)
Leukemia $128,641 ($128,548–$128,734) $99,506 ($99,436–$99,576)
Thyroid $84,113 ($83,918–$84,308) $54,921 ($54,799–$55,043)
Testis $75,458 ($75,238–$75,678) $48,550 ($48,417–$48,683)
All other tumour sites $76,634 ($76,584–$76,683) $61,520 ($61,483–$61,558)
Females
Head and neck $95,704 ($95,558–$95,850) $74,332 ($74,220–$74,443)
Esophagus $76,240 ($76,148–$76,332) $67,714 ($67,638–$67,790)
Gastric $70,738 ($70,654–$70,821) $61,429 ($61,364–$61,494)
Colorectal $83,535 ($83,480–$83,591) $65,944 ($65,902–$65,986)
Liver $50,349 ($50,175–$50,523) $43,221 ($43,076–$43,366)
Pancreas $67,424 ($67,377–$67,472) $59,192 ($59,152–$59,232)
Lung $52,940 ($52,916–$52,964) $46,198 ($46,177–$46,218)
Melanoma $70,249 ($70,108–$70,390) $45,730 ($45,637–$45,823)
Female breast $110,346 ($110,300–$110,392) $76,113 ($76,081–$76,144)
Corpus uteri $70,587 ($70,471–$70,703) $49,841 ($49,762–$49,921)
Cervix $69,230 ($69,094–$69,367) $50,208 ($50,119–$50,296)
Ovary $70,831 ($70,754–$70,908) $58,433 ($58,374–$58,492)
Bladder $75,617 ($75,459–$75,775) $57,430 ($57,312–$57,548)
Renal $76,638 ($76,511–$76,766) $59,183 ($59,088–$59,279)
Brain $107,188 ($107,101–$107,274) $80,728 ($80,672–$80,784)
Lymphoma $107,514 ($107,371–$107,656) $77,860 ($77,758–$77,961)
Myeloma $119,958 ($119,845–$120,072) $97,988 ($97,894–$98,082)
Leukemia $138,749 ($138,617–$138,881) $106,112 ($106,015–$106,208)
Thyroid $86,781 ($86,633–$86,929) $54,625 ($54,537–$54,714)
All other tumour sites $80,820 ($80,748–$80,891) $63,505 ($63,451–$63,558)
* Phase-specific net cost of care estimates were applied to 25-year survival probabilities among cancer patients diagnosed 1997–2007. All cost estimates are in
2009 dollars
Data sources: Ontario Cancer Registry data (survival), and Cancer Care Ontario and administrative health data housed at the Institute for Clinical Evaluative
Sciences (mean net costs by phase of care)
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and included a large population-based sample of all adults
age 18+ diagnosed with cancer; most studies have included
patients age 65+ only. We estimated costs for cancer sites
that are not typically reported, such as multiple myeloma,
and those more common among younger adults, such
as thyroid and testicular cancers. These estimates are
currently lacking in the literature. We used detailed
costing methods and considered the majority of health
services covered by the public third-party payer under a
comprehensive universal health care insurance plan. We
included costs for resources, such as outpatient prescrip-
tion drugs and long-term care, which were not included
in SEER-Medicare studies [29]. These make up a signifi-
cant proportion of costs for older patients with cancer.
We also made use of more rigorous matching than previ-
ous work [4], as imperfect matching can produce biased
net cost estimates [38], and we used separately matched
controls for the initial and terminal phases. Nonetheless,
we were limited by number of variables we could match
on. Given the similarity in patterns of care across the de-
veloped world, these results may be relevant to other juris-
dictions that lack comprehensive population-based cancer
cost estimates for all adults [39].
We were unable to provide cost estimates by cancer
stage; this information was not available in the Ontario
Cancer Registry during our analysis period. We were only
able to capture costs for outpatient drugs covered by the
public provincial drug program (patients age 65+ and spe-
cial cases). As such, our cost estimates are likely an under-
estimate of the cost of drugs for managing treatment side
effects and/or drugs for symptom management in advanced
disease. Furthermore, we only estimated direct costs in-
curred by the public third-party payer; we did not account
for other relevant costs, such as out-of-pocket or time and
productivity costs. These costs are generally not readily
available as they need to be collected and/or estimated
through patient questionnaires. Out-of-pocket and time
costs can vary by cancer site and socioeconomic status [40].
Previous work has shown that even in Ontario, a jurisdic-
tion with public health care insurance, out-of-pocket and
time costs can represent a significant burden for low-
income prostate cancer patients, and have an important
impact on their quality of life [41]. This should also be the
focus of future research.
Finally, the estimation of lifetime costs required making
some assumptions. First, we assumed all patients would be
deceased 25 years after diagnosis [29]. This may be valid for
most cancer sites, especially those diagnosed among older
patients, but not for those typically diagnosed among
younger patients, such as thyroid and testicular cancers.
Nonetheless, to ensure comparability, we estimated life-
time costs in the same manner for all cancer sites.
Second, we assumed no structural changes over time in
technology or medical practice patterns; this is likely
unrealistic but a necessary simplification in order to
make use of our existing cost estimates.
Conclusions
In conclusion, our results suggest that costs of cancer care
are substantial and vary by cancer site, phase of care and
time horizon of analysis. These cost estimates are valuable
to decision makers to understand the economic burden of
cancer care. In addition, they may be useful inputs to re-
searchers undertaking cancer-related economic evaluations.
Endnotes
1The covariance of costs for cases and controls is
independent, given the conditional independence of
the comorbidity and socio-demographic variables after
matching.
2We have adjusted the formula as found in Yabroff et al.,
2008 to address a typo.
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